Tuesday, November 1, 2022 Daily Archives

Less is More in mRNA Therapeutics: Developing Big Ideas in Small Scale

This webcast features: Linda Mathiasson, Strategic Customer Lead, Cytiva. Messenger RNA technology has changed the way therapies are developed. The overall potential of mRNA is clear, with mRNA therapeutics being developed in many research areas. The speed and potential cost gains of mRNA technology make it an interesting technology for personalized medicine. However, much of the current equipment used in manufacturing is repurposed from the biotech industry and is designed for much larger scales than needed for mRNA. In this…

Vetter Pharma ups storage capacity with warehouse expansion

Vetter Pharma has completed its €20 million ($19 million) warehouse expansion, which it says will help meet customer supply demands. Contract development manufacturing organization (CDMO) Vetter says that the fully automated building located in Ravensburg, Germany optimizes the firm’s logistical infrastructure by providing storage space for materials it considers having high-stock turnover rates, such as packaging components. The firm claims that construction of the warehouse, which began in April 2021, will mean that “valuable capacity” is freed up in the…

Resource Roadmap to Screening Success: Cell-based Therapy Edition

Due to the tight link between cell culture conditions and final product quality attributes, thorough evaluation of raw materials and process parameters is critical to the development of cell-based therapies. Screening a wide array of process inputs using conventional methods and variable reagents can be costly and time consuming. This Resource Roadmap illustrates the use of the Sartorius Screening Ensemble to enable broad exploration early in development while also accelerating experimental design, execution, and validation Read this Resource Roadmap to…

Gradual capacity rollouts reducing lead times, says Thermo

Bioproduction capital expenditure projects totaling upwards of $600 million are coming online and bringing lead times back to a pre-pandemic level, says Thermo Fisher. In March 2021, Thermo Fisher Scientific announced plans to invest “more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022.” This included a range of capacity expansion projects focused on single-use technologies, chromatography resins, and cell culture media already in the company’s pipeline either already underway or expedited due to COVID-19-related…